Sorrento Therapeutics Inc (SRNE) Expected to Announce Quarterly Sales of $12.73 Million

Brokerages forecast that Sorrento Therapeutics Inc (NASDAQ:SRNE) will report sales of $12.73 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Sorrento Therapeutics’ earnings. The lowest sales estimate is $5.50 million and the highest is $19.96 million. Sorrento Therapeutics posted sales of $4.02 million during the same quarter last year, which would indicate a positive year over year growth rate of 216.7%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, March 27th.

On average, analysts expect that Sorrento Therapeutics will report full year sales of $12.73 million for the current fiscal year, with estimates ranging from $136.90 million to $151.41 million. For the next fiscal year, analysts forecast that the business will post sales of $24.15 million per share, with estimates ranging from $20.80 million to $27.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Sorrento Therapeutics.

How to Become a New Pot Stock Millionaire

SRNE has been the topic of several research reports. BidaskClub upgraded shares of Sorrento Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. ValuEngine upgraded shares of Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective (up from $20.00) on shares of Sorrento Therapeutics in a report on Tuesday, January 16th. Finally, Oppenheimer reiterated a “buy” rating and issued a $9.00 price objective on shares of Sorrento Therapeutics in a report on Friday, January 19th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Sorrento Therapeutics currently has an average rating of “Buy” and a consensus target price of $15.00.

In other Sorrento Therapeutics news, major shareholder Pacific Medtech (Bvi) Ltd Asia sold 684,288 shares of the company’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $7.56, for a total value of $5,173,217.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Abg Management Ltd sold 310,000 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $7.64, for a total transaction of $2,368,400.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,215,009 shares of company stock worth $9,185,885. Corporate insiders own 5.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. MYDA Advisors LLC acquired a new position in shares of Sorrento Therapeutics in the fourth quarter valued at about $114,000. Monashee Investment Management LLC acquired a new position in shares of Sorrento Therapeutics in the fourth quarter valued at about $119,000. Alambic Investment Management L.P. acquired a new position in shares of Sorrento Therapeutics in the fourth quarter valued at about $151,000. Gotham Asset Management LLC acquired a new position in shares of Sorrento Therapeutics in the fourth quarter valued at about $163,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Sorrento Therapeutics by 408.4% in the second quarter. Dimensional Fund Advisors LP now owns 51,889 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 41,683 shares in the last quarter. Institutional investors and hedge funds own 12.24% of the company’s stock.

SRNE stock traded down $0.63 during trading hours on Friday, hitting $6.92. 4,452,499 shares of the company’s stock traded hands, compared to its average volume of 3,533,631. Sorrento Therapeutics has a 12-month low of $1.50 and a 12-month high of $10.65. The firm has a market capitalization of $708.22, a P/E ratio of -13.59 and a beta of 2.05. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.54 and a current ratio of 0.38.

TRADEMARK VIOLATION WARNING: This report was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3293538/sorrento-therapeutics-inc-srne-expected-to-announce-quarterly-sales-of-12-73-million.html.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.

Get a free copy of the Zacks research report on Sorrento Therapeutics (SRNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sorrento Therapeutics (NASDAQ:SRNE)

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Wedbush Reaffirms “Outperform” Rating for Steve Madden
Wedbush Reaffirms “Outperform” Rating for Steve Madden
Catasys  Rating Lowered to Strong Sell at Zacks Investment Research
Catasys Rating Lowered to Strong Sell at Zacks Investment Research
Robert W. Baird Reiterates Buy Rating for TSYS
Robert W. Baird Reiterates Buy Rating for TSYS
Subaru  Stock Rating Lowered by Zacks Investment Research
Subaru Stock Rating Lowered by Zacks Investment Research
Equity BancShares  Stock Rating Reaffirmed by Sandler O’Neill
Equity BancShares Stock Rating Reaffirmed by Sandler O’Neill
Varian Medical Systems  Scheduled to Post Quarterly Earnings on Tuesday
Varian Medical Systems Scheduled to Post Quarterly Earnings on Tuesday


© 2006-2018 Ticker Report. Google+.